NCT00820950 - A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

April 30, 2009

Conditions

Psoriasis

Interventions

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 0.5%

DRUG

Dovonex® calcipotriene 0.005%

Cream applied once or twice daily for up to 56 days.

DRUG

Diprolene® AF betamethasone dipropionate 0.05% cream.

Cream applied once or twice daily for up to 56 days

DRUG

Placebo cream

Cream applied once or twice daily for 56 days

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 1.0%

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 1.5%

Trial Locations (6)

Vallejo

Boston

Rochester

Stony Brook

Portland

Philadelphia